Case Remain for Bal...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$2.52 -0.02 | -0.79%
05/20/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.54 |
| 52 Week High | 4.50 |
| 52 Week Low | 1.54 |
| Avg. Daily Vol. (Mil) | 0.69 |
| Beta (3 year) | 1.04 |
| Share Related Items | |
| Mkt Cap (Mil) | 254.65 |
| Shares Out (Mil) | 100.25 |
| Float (Mil) | 78.16 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.90 |
| Current Ratio | 2.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 4.61 |
| Price/Book | 0.00 |
| Price/Cash Flow | -9.00 |
| Per Share Data | |
| Earnings | -0.29 |
| Sales | 0.55 |
| Book Value | 0.00 |
| Cash Flow | -0.28 |
| Business Summary | |
|---|---|
| Dyax Corporation is a biotechnology company, which is engaged in the discovery, development and commercialization of biopharmaceuticals for unmet medical needs. | |
| General Information | |
| 55 Network Drive
Burlington, MA 01803 |
|
| www.dyax.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 125 | |
| CEO: Gustav A. Christensen | |
| Short Interest | |
| Current Month (Mil) | 7.68 |
| Previous Month (Mil) | 7.51 |
| Short Interest Ratio (Days) | 8.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -61.50 |
| Return on Investments | -141.00 |
| Profitability | |
| Gross Margin | 97.60 |
| EBIT Margin | -33.50 |
| Profit Margin | -52.90 |
Portfolios with DYAX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
Latest DYAX Headlines from TheStreet
- 5 Biotech Stocks Poised for Breakouts 07.27.12 | 01:07 pm
- Dyax Corporation CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.19.12 | 08:07 pm
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
Press Releases for DYAX
- Dyax Corp. To Participate In The 25th Annual ROTH Conference - Business Wire 03.12.13 | 07:03 am
- Dyax Announces Management Change - Business Wire 03.08.13 | 08:03 am
- Dyax Presents DX-2930 Data At The 2013 American Academy Of Allergy, Asthma And Immunology Annual Meeting - Business Wire 02.25.13 | 07:02 am
- Dyax Corp. To Participate In Upcoming 2013 Healthcare Conferences - Business Wire 02.20.13 | 07:02 am
- Dyax Corp. Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.13.13 | 04:02 pm
- Dyax Corp. And CVie Therapeutics Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In China, Hong Kong And Macau - Business Wire 02.07.13 | 07:02 am
- Dyax Corp. To Participate In The Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Dyax Corp. To Host Fourth Quarter And Year End 2012 Earnings Call And Webcast - Business Wire 02.05.13 | 07:02 am
- Dyax Corp. And Novellus Biopharma AG Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In Latin America - Business Wire 01.31.13 | 07:01 am
- Behind The Success - Research Report On Corcept Therapeutics Inc. And Dyax Corp. - PR Newswire 01.23.13 | 08:01 am
Partner Headlines for DYAX
- Microvision CRASHES 24% to Lead 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.18.12 | 09:06 am
- Barclays UPGRADES Dollar General to Overweight and 4 Stocks on Analyst Radars - Wall St. Cheat Sheet 06.15.12 | 04:06 am
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
